CYNGN SINGAPORE PTE. LTD.
UEN: 201535712N
CYNGN SINGAPORE PTE. LTD.(201535712N) is a Singapore business with registered business address at 7 STRAITS VIEW, 12-0, MARINA ONE EAST TOWER, Singapore 18936. They specialise in the area of DEVELOPMENT OF OTHER SOFTWARE AND PROGRAMMING ACTIVITIES N.E.C. and INFORMATION TECHNOLOGY CONSULTANCY (EXCEPT CYBERSECURITY).
| Company Name | CYNGN SINGAPORE PTE. LTD. |
| Unique Entity Number | 201535712N |
| Entity Type | Local Company |
| Entity Status | Live Company |
| Incorporate Day | 25 September 2015 |
| Address |
7 STRAITS VIEW #12-0 MARINA ONE EAST TOWER Singapore 18936 |
| Products / Services |
DEVELOPMENT OF OTHER SOFTWARE AND PROGRAMMING ACTIVITIES N.E.C. INFORMATION TECHNOLOGY CONSULTANCY (EXCEPT CYBERSECURITY) |
| Number of Officers | 4 |
| Paid Up Capital | USD 1 |
Breaking! Business News
TOGA Limited Names Marcum LLP as AuditorTOGA Limited Names Marcum LLP as AuditorGlobeNewswireJuly 13, 2020LAS VEGAS, July 13, 2020 (GLOBE ...
Read More
Aviation Week Network’s MRO Series Goes Virtual this Fall With MRO Asia-Pacific and MRO TransAtlanticAviation Week Network’s MRO Series Goes Virtual this Fall With MRO Asia-Pacific and MRO TransAtla...
Read More
3B Future Health Fund announces new investment in iOnctura3B Future Health Fund announces new investment in iOncturaGlobeNewswireJuly 14, 20203B Future Health...
Read More
Leading Indonesian Telco Selects ForgeRock to Modernize Its Identity InfrastructureLeading Indonesian Telco Selects ForgeRock to Modernize Its Identity InfrastructureXL Axiata undert...
Read More
CNA Transitions to AIR Worldwide as its Primary Catastrophe Risk Management PlatformCNA Transitions to AIR Worldwide as its Primary Catastrophe Risk Management PlatformGlobeNewswireJul...
Read More
Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in EuropeOvid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture...
Read More
Trip.com Group releases “2020 Dragon Boat Festival Holiday Big Data Report”Trip.com Group releases “2020 Dragon Boat Festival Holiday Big Data Report”GlobeNewswireJuly 13,...
Read More
Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of SARS-CoV-2 Neutralizing Antibody JS016 in ChinaJunshi Biosciences Announces Completion of Enrollment in Phase I Trial of SARS-CoV-2 Neutralizing An...
Read More